Search clinical trials for: New Pazopanib formulation

Total 2898 results

The Netherlands Cancer Institute

Completed

Study With Improved Solubility Pazopanib

Pharmacokinetics of Pazopanib

Netherlands
Genfit
Naturalpha; SGS Aster S.A.S.

Completed

Comparative Bioavailability - Gender Effect - Single and Multiple Ascending Dose Safety and Pharmacokinetic Study of GFT505

Cardiovascular Diseases | Metabolic Diseases | Diabetes Mellitus, Type 2 | Type 2 Diabetes | Dyslipidemia | Obese

France
GlaxoSmithKline

Completed

A Healthy Volunteer Study to Investigate the Relative Bioavailability of Two Forms of GSK598809 Capsules.

Substance Dependence

United Kingdom
Eli Lilly and Company

Completed

A Study of LY3039478 in Healthy Participants

Healthy

United States
Takeda

Completed

A Comparison of the Safety and Immunogenicity of Various Schedules of Dengue Vaccine in Healthy Adult Volunteers

Healthy

United States
GlaxoSmithKline

Completed

Bioequivalence Study of Aciclovir 5% Cream in Japanese Healthy Volunteers

Herpes Labialis

Japan
ESM Technologies, LLC

Completed

Efficacy & Safety Study of Natural Eggshell Membrane (NEM) for the Treatment of Joint & Connective Tissue Disorders

Osteoarthritis | Fibromyalgia

United States
Boehringer Ingelheim

Terminated

Study to Evaluate Pharmacokinetics of Dipyridamole in Three New Formulations of Asasantin ER in Healthy Female and Male Subjects

Healthy
Takeda

Completed

Study of Dose Adjustment From Levothyroxine to a New Levothyroxine Sodium Test Formulation

Hypothyroidism

Belgium
Tibotec Pharmaceuticals, Ireland

Completed

TMC114-TiDP3-C182 - A Study to Compare the Oral Bioavailability of a 800 mg Prototype Tablet Formulation of Darunivar (DRV) to That of the 400 mg Commercial Tablet Formulation in the Presence of Low Dose Ritonavir, Under Fasted and Fed Conditions

HIV Infections
Derming SRL

Completed

Evaluation of Tolerance and Trichological Efficacy of a Food Supplement

Telogen Effluvium
ViiV Healthcare

Completed

Relative Bioavailability Study of Phase III Tablet Formulation of Cabotegravir

Infection, Human Immunodeficiency Virus

United States
Embera NeuroTherapeutics, Inc.
National Institute on Drug Abuse (NIDA)

Completed

Single Dose Crossover Comparative Bioavailability and Food Effect Study of Two EMB-001 Formulations

Cocaine Use Disorder

United States
AbbVie (prior sponsor, Abbott)

Completed

A Study in Rheumatoid Arthritis (RA) Patients to Compare Two Formulations of Adalimumab for Pharmacokinetic, Pharmacodynamic and Safety

Rheumatoid Arthritis

United States, Belgium, Czech Republic, Germany, Puerto Rico, Romania, Slovakia
Boehringer Ingelheim

Completed

Bioavailability of Dipyridamole of Asasantin p.o. in Three Experimental Formulations Relative to the Standard Formulation in Healthy Male Subjects

Healthy
TaiGen Biotechnology Co., Ltd.

Completed

Study to Evaluate the PK, Relative Bioavailability and Safety of TG-2349 With Single Oral Dose Under Fed Condition in Healthy Volunteers

Healthy

United States
Boehringer Ingelheim

Completed

Study to Compare the Pharmacokinetics of Dipyridamole in Three Different Asasantin Extended Release (ER) Formulations in Healthy Male and Female Volunteers

Healthy
ViiV Healthcare

Completed

A Study to Assess The Relative Bioavailability of New Tablet Formulations of GSK1265744 in Healthy Adult Subjects

Infection, Human Immunodeficiency Virus

United States
Washington University School of Medicine
Novartis Pharmaceuticals

Completed

Pazopanib Plus Cetuximab for Incurable Head and Neck Squamous Cell Carcinoma (HNSCC) (HNSCC)

Squamous Cell Carcinoma of the Head and Neck

United States
EMD Serono

Completed

Rebif New Formulation (RNF) Quality of Life (QOL) Study (RebiQoL)

Relapsing Multiple Sclerosis

United States
Boehringer Ingelheim

Completed

Pharmacokinetics and Safety of BILR 355 in Healthy Male Volunteers

Healthy
GlaxoSmithKline

Completed

Relative Bioavailability Study of Marketed and Lower Dose Ambrisentan in Healthy Adult Participants

Hypertension, Pulmonary

United Kingdom
Cure HHT
University of North Carolina

Not yet recruiting

Pazopanib for the Treatment of Epistaxis in Hereditary Hemorrhagic Telangiectasia

Epistaxis | Hereditary Hemorrhagic Telangiectasia
AbbVie (prior sponsor, Abbott)

Completed

Study in Rheumatoid Arthritis for Subjects Who Completed Preceding Study M13-390 With Adalimumab

Rheumatoid Arthritis

United States, Belgium, Czech Republic, Germany, Puerto Rico, Romania, Slovakia
Allergan

Completed

Safety and Efficacy Study of New Eye Drop Formulations With Refresh Tears® in Patients With Dry Eye Disease

Dry Eye Syndromes

Canada, Australia
GlaxoSmithKline

Completed

Immunogenicity & Safety Study of GSK Biologicals' 208136 Vaccine Formulated With New Measles and Rubella Working Seeds

Measles | Rubella | Mumps | Varicella

Taiwan, Singapore
Hillel Yaffe Medical Center

Unknown

Safety of Formalin-free Fixatives for In-Vivo Fixation of Skin Lesions.

Skin Abnormality

Israel
Bayer

Completed

Moisturizing Effect of Two Dexpanthenol Formulations

Skin Abnormalities

France
Boehringer Ingelheim

Completed

Pharmacokinetics of Two Different Persantin® Sugar Coated Tablets in Healthy Male Volunteers

Healthy
Illinois CancerCare, P.C.

Terminated

GW786034 in Patients With Non Small Cell Lung Cancer 3rd Line

Non Small Cell Lung Cancer

United States
Bayer

Completed

Efficacy of Dexpanthenol in Thermic Erythema

Erythema

France
Alcon Research

Completed

Pharmacokinetic and Safety Study of Travoprost 0.004% in Pediatric Glaucoma Patients

Ocular Hypertension | Glaucoma
Sanofi

Completed

Euglycemic Clamp Study Comparing Two New Insulin Glargine Formulations in Subjects With Type 1 Diabetes Mellitus

Type1 Diabetes

Germany
Fondazione IRCCS Istituto Nazionale dei Tumori,...

Completed

Prospective Translational Study Investigating Possible Molecular prEdictors of Resistance to First-Line pazopanIb (PIPELINE)

Metastatic Renal Cell Carcinoma
Institut Claudius Regaud
Novartis

Terminated

Phase I Clinical and Pharmacokinetic Study of Pazopanib in a Population of Frail Elderly Patients According SIOG Criteria (VOTRAGE)

Metastatic Cancer (Different Solid Tumour Types)

France
Gynecologic Oncology Group
GlaxoSmithKline

Withdrawn

Pazopanib for Treating Uterine Leiomyosarcoma

Uterine Leiomyosarcoma
Samsung Medical Center

Completed

Study to Evaluate the Safety and Efficacy of Pazopanib, in Subject With Refractory Solid Tumors

Refractory Solid Tumors

Korea, Republic of
Spanish Oncology Genito-Urinary Group

Completed

Spanish Retrospective Study to Evaluate the Efficacy and Safety of Targeted Therapies After Pazopanib as First-line Therapy (SPAZO)

Metastatic Renal Cell Carcinoma

Spain
GlaxoSmithKline

Completed

A Study to Evaluate Pazopanib Tablets in Patients Who Have Neovascular Age-related Macular Degeneration

Macular Degeneration

United States
Samsung Medical Center

Completed

pazopanib_NCRCC,Ph2 STUDY

Locally Advanced or Metastatic Non-clear Cell Type Renal Cell Carcinoma

Korea, Republic of
Samsung Medical Center

Completed

Study of Pazopanib Monotherapy in Patients With Unresectable, Metastatic Neuroendocrine Tumor

Neuroendocrine Tumor

Korea, Republic of
EMD Serono

Completed

12-week Study to Evaluate RebiSmart™ Suitability for Self Injection in Relapsing Multiple Sclerosis.

Multiple Sclerosis

United States, Canada, Germany, Italy, Spain, Sweden
Alcon Research

Withdrawn

Three Month Safety and Efficacy Study of TRAVATAN® Versus Travoprost Ophthalmic Solution, 0.004%

Ocular Hypertension | Open Angle Glaucoma
Novartis Pharmaceuticals

Completed

Study of Efficacy, Safety, and Quality of Life of Pazopanib in Patients With Advanced and/or Metastatic Renal Cell Carcinoma After Prior Checkpoint Inhibitor Treatment (IO-PAZ)

Metastatic Renal Cell Carcinoma | Advanced Renal Cell Carcinoma

Spain, Germany, United States, Austria, Czechia, United Kingdom, Argentina, Hungary, France, Canada, Chile
Samsung Medical Center

Completed

Single-arm Study to Evaluate the Safety and Efficacy of Pazopanib, in Subjects With FGFR2 Amplification, FGFR2 Mutation Refractory Solid Tumors

Refractory Solid Tumors

Korea, Republic of
Grupo Espanol de Investigacion en Sarcomas
GlaxoSmithKline

Completed

Activity and Tolerability of Pazopanib in Advanced and/or Metastatic Liposarcoma. A Phase II Clinical Trial

Advanced and / or Metastatic Liposarcoma

Spain, Germany
Grupo Espanol de Tumores Neuroendocrinos

Completed

Pazopanib as Single Agent in Advanced NETs

Advanced/Metastatic Neuroendocrine Tumors

Spain
Seoul National University Hospital
Samsung Medical Center; Asan Medical Center; Seoul National University Bundang... and other collaborators

Terminated

Pazopanib for Metastatic Alveolar Soft Part Sarcoma

Metastatic Alveolar Soft Part Sarcoma

Korea, Republic of
Interessenverband zur Qualitätssicherung der Arbeit...
OnkoDataMed GmbH

Terminated

Optimizing Pazopanib Exposure in RCC Patients (OPERA)

Metastatic Renal Cell Carcinoma | Locally Advanced Renal Cell Carcinoma

Germany
National Taiwan University Hospital
GlaxoSmithKline

Unknown

Pazopanib in Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma

Head and Neck Squamous Cell Carcinoma

Taiwan

3

Subscribe